Evidence map›Paper›PMID 38532666›Full record

ArticleInfluenza and other respiratory viruses2024

Seroprevalence of SARS-CoV-2 in 10 Regional Capitals of Cameroon, October-December 2020.

Karampreet Sachathep, Yen T Duong, Giles Reid, Emily Kainne Dokubo, Judith D Shang, Clement B Ndongmo, Ekali Gabriel, G Tharp, Laura Eno Dimite, Adama N'Dir and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Influenza and other respiratory viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Karampreet SachathepICAP at Columbia University, New York, New York, USA.ORCID 0009-0000-4451-0561
Yen T DuongICAP at Columbia University, New York, New York, USA.
Giles ReidICAP at Columbia University, New York, New York, USA.
Emily Kainne DokuboUS Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Judith D ShangUS Centers for Disease Control and Prevention, Yaoundé, Cameroon.
Clement B NdongmoUS Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Ekali GabrielICAP in Cameroon, Yaoundé, Cameroon.
G TharpDepartment of Sociomedical Sciences, Mailman School of Public Health, New York, New York, USA.
Laura Eno DimiteUS Centers for Disease Control and Prevention, Yaoundé, Cameroon.
Adama N'DirUS Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Gordon OkpuUS Centers for Disease Control and Prevention, Yaoundé, Cameroon.
Francis M OgollahICAP at Columbia University, New York, New York, USA.
Dubliss NguafackICAP in Cameroon, Yaoundé, Cameroon.
Martin C NtseICAP in Cameroon, Yaoundé, Cameroon.
Gili HrusaICAP at Columbia University, New York, New York, USA.
Katherine YuenglingICAP at Columbia University, New York, New York, USA.
Megan TebbenhoffDepartment of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, USA.
Essomba RenéMinistry of Health, Yaoundé, Cameroon.
Ngo Sack FrançoiseMinistry of Health, Yaoundé, Cameroon.
Naah Tabala FelicityMinistry of Health, Yaoundé, Cameroon.
Marie Claire OkomoMinistry of Health, Yaoundé, Cameroon.
Anne-Cecile Zoung-Kanyi BissekMinistry of Health, Yaoundé, Cameroon.
Tiffany G HarrisICAP at Columbia University, New York, New York, USA.

Funding

ACL HHS U01GH002171CDC HHS U2GGH002216CGH CDC HHS U01 GH002171
6 · The paper itself

Abstract

backgroundCameroon was among the most affected African countries during the first wave of the COVID-19 pandemic; however, the true prevalence of SARS-CoV-2 remains unknown.

methodsFrom October to December 2020, we conducted a cross-sectional, age-stratified SARS-CoV-2 seroepidemiological survey at 30 purposively selected community-based sites across Cameroon's 10 regional capitals, sampling 10,000 individuals aged 5 years or older. We employed a parallel SARS-CoV-2 antibody testing algorithm (WANTAI ELISA and Abbott Architect) to improve both the positive predictive value and negative predictive value of seroprevalence.

resultsThe overall weighted and adjusted seroprevalence of SARS-CoV-2 antibodies across the 10 urban capitals of Cameroon was 10.5% (95% CI: 9.1%-12.0%) among participants aged ≥5 years. Of the 9332 participants, 730 males (13.1%, 95% CI: 11.5%-14.9%) had SARS-CoV-2 antibodies compared to 293 females (8.0%, 95% CI: 6.8%-9.3%). Among those who reported a comorbidity at the time of testing, 15.8% (95% CI: 12.8%-19.4%) were seropositive. We estimated that over 2 million SARS-CoV-2 infections occurred in the 10 regional capitals of Cameroon between October and December 2020, compared to 21,160 cases officially reported at that time translating to one laboratory-confirmed case being reported for every 110 SARS-CoV-2 infections across the 10 urban capitals.

conclusionThis study's findings point to extensive and under-reported circulation of SARS-CoV-2 in Cameroon-an almost 100-fold more cases compared to the number of cases reported to the World Health Organization. This finding highlights the importance of conducting serosurveys, especially in settings where access to testing may be limited and to repeat such surveys as part of pandemic tracking.

Indexed as

COVID-19SARS-CoV-2Antibodies, ViralCameroonCross-Sectional StudiesFemaleHumansMalePandemicsSeroepidemiologic StudiesAntibodies, ViralCameroonCOVID‐19SARS‐CoV‐2serosurvey

Identifiers

PMID38532666
PMCPMC10966350

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.